Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gene prediction

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    27 result(s) found for: Gene prediction. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2020-002165-34 Sponsor Protocol Number: RC19_0292 Start Date*: 2020-12-03
    Sponsor Name:CHU of Nantes
    Full Title: Predictive Signature of Benralizumab Response
    Medical condition: Severe asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-004182-26 Sponsor Protocol Number: ELIA Start Date*: 2009-02-02
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Antidepressive efficacy, safety, tolerability and genetic response predictors of lithium augmentation in Escitalopram-treated patients with major depression
    Medical condition: 30-40% of depressed patients do not respond to the first course of drug treatment chosen. Over 50% of nonresponders to the first treatment also do not respond to a second, different treatment . Of ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002071-34 Sponsor Protocol Number: ALLOCATE Start Date*: 2019-10-31
    Sponsor Name:Vejle Hospital
    Full Title: Allocation of patients with pre-treated solid tumors to anti-cancer therapy based on gene expression drug response prediction - a phase II basket trial
    Medical condition: Breast cancer Ovarian cancer Lung cancer Colorectal cancer Prostate cancer Pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10072737 Advanced breast cancer LLT
    20.0 100000004864 10033130 Ovarian cancer NOS LLT
    20.1 100000004864 10080083 Advanced lung cancer LLT
    20.0 100000004864 10052362 Metastatic colorectal cancer LLT
    20.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    20.0 100000004864 10036910 Prostate cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000545-40 Sponsor Protocol Number: FELZ01 Start Date*: 2021-08-01
    Sponsor Name:Medical University of Vienna
    Full Title: Safety, Tolerability and Efficacy of Monoclonal CD38 Antibody Felzartamab in Late Antibody-Mediated Renal Allograft Rejection – A Phase 2 Pilot Trial
    Medical condition: Late active or chronic active antibody-mediated rejection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002696-10 Sponsor Protocol Number: CCPK850X2202 Start Date*: 2018-05-09
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label first-in-human single ascending dose study to explore the safety, tolerability and efficacy of subretinal administration of CPK850 gene therapy in patients with retinitis pigmentosa c...
    Medical condition: retinitis pigmentosa caused by biallelic mutations in the RLBP1 gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-003160-19 Sponsor Protocol Number: ASL608LIOM01 Start Date*: 2008-09-07
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST
    Full Title: CETUXIMAB PLUS IRINOTECAN IN PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER PATIENTS SELECTED ON THE BASIS OF KRAS MUTATION AND EGFR INTRON 1 CA TANDEM REPEATS: PHASE II PROSPECTIVE STUDY AND RETR...
    Medical condition: colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001167 Adenocarcinoma of colon LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-006024-11 Sponsor Protocol Number: HD/BN-2005-MM-R Start Date*: 2006-11-08
    Sponsor Name:University hospital of Bonn
    Full Title: Prospective, open label, multi center phase II clinical trial of oral BAY 43-9006 (Sorafenib) in patients with relapsed or refractory multiple myeloma
    Medical condition: Relapsed or refractory multiple myeloma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001560-14 Sponsor Protocol Number: FJD-RA-TOF-60418809 Start Date*: 2021-08-13
    Sponsor Name:FUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTE
    Full Title: Single-center, open-label, uncontrolled clinical trial to evaluate the association between the expression of the JAK / STAT pathway and the response to tofacitinib in patients with refractory rheum...
    Medical condition: Refractory rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001730-26 Sponsor Protocol Number: 205756 Start Date*: 2017-10-30
    Sponsor Name:Orchard Therapeutics (Europe) Ltd
    Full Title: A single arm, open label, clinical study of cryopreserved autologous CD34+ cells transduced with lentiviral vector containing human ARSA cDNA OTL-200, for the treatment of early onset Metachromatic...
    Medical condition: Metachromatic Leukodystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10067609 Metachromatic leukodystrophy PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-002480-15 Sponsor Protocol Number: M14REP Start Date*: 2014-10-15
    Sponsor Name:The Dutch Working Group on Immunotherapy of Oncology (WIN-O)
    Full Title: A Phase II, Open-Label, Multicenter Study of Vemurafenib plus Cobimetinib (GDC-0973) in Unresectable Stage IIIc or Metastatic Melanoma; Response Monitoring and Resistance Prediction with Positron E...
    Medical condition: BRAFV600-mutation positive patients with unresectable stage IIIc or IV melanoma.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001205-73 Sponsor Protocol Number: IMP4297-202 Start Date*: 2021-08-24
    Sponsor Name:IMPACT Therapeutics, Inc.
    Full Title: A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Phase II Study to Evaluate Senaparib Maintenance in mCRPC Patients with Homologous Recombination Repair Gene Alterations after Docetax...
    Medical condition: metastatic castration-resistant prostate cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) FR (Completed) ES (Ongoing) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002636-82 Sponsor Protocol Number: OTL-200-07 Start Date*: 2019-12-02
    Sponsor Name:Orchard Therapeutics (Europe) Limited
    Full Title: An open label, non-randomised trial to evaluate the safety and efficacy of a single infusion of OTL-200 in patients with Late Juvenile (LJ) Metachromatic Leukodystrophy (MLD)
    Medical condition: Metachromatic Leukodystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10067609 Metachromatic leukodystrophy PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-005028-40 Sponsor Protocol Number: MOLTO Start Date*: 2019-08-29
    Sponsor Name:AZIENDA OSPEDALIERA AO OSPEDALE NIGUARDA CA' GRANDA
    Full Title: A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination with Atezolizumab and Obinutuzumab in Richter Transformation of CLL
    Medical condition: Richter syndrome of chronic lymphocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058728 Richter's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-000287-29 Sponsor Protocol Number: ET-FES00119 Start Date*: 2014-08-13
    Sponsor Name:Università del Piemonte Orientale
    Full Title: EARLY PREDICTION OF EFFICACY OF ENDOCRINE THERAPY IN BREAST CANCER: PILOT STUDY AND VALIDATION WITH 18F FLUOROESTRADIOL (FES) PET/CT
    Medical condition: Patients with histologically or cytologically confirmed ER-positive MBC at first evidence of metastatic disease.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) DE (Ongoing) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-006180-36 Sponsor Protocol Number: 22071-24071 Start Date*: 2011-01-18
    Sponsor Name:EORTC - European Organisation for Research and Treatment of Cancer
    Full Title: Randomized Phase III trial on postoperative chemoradiation in combination with anti EGFR-antibody versus postoperative chemoradiation in head and neck squamous cell carcinomas (HNSCC) with high ris...
    Medical condition: head and neck squamous cell carcinomas (HNSCC) with high risk of locoregional recurrence
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067821 Head and neck cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) SI (Completed)
    Trial results: View results
    EudraCT Number: 2015-003429-32 Sponsor Protocol Number: ImbruVeRCHOP-Trial Start Date*: 2017-02-09
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: “Ibrutinib (Imbruvica®), Bortezomib (Velcade®) s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI ≥ 2”
    Medical condition: untreated CD20-positive DLBCL-like aggressive Non-Hodgkin’s lymphoma, 61-80 years of age with unfavorable risk profile (IPI ≥ 2)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005393-73 Sponsor Protocol Number: ERLOPET_01 Start Date*: 2007-09-14
    Sponsor Name:University Cologne
    Full Title: A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT- PET for Early Prediction of Non-Progression in Patients with Advanced Non Small Cell Lung Cancer (NSCLC) treated with Erlotinib and t...
    Medical condition: The trial will be conducted in patients with non-small cell lung cancer in stage IIIb - IV
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001189-98 Sponsor Protocol Number: NICSA Start Date*: 2017-08-28
    Sponsor Name:Aarhus Universitet
    Full Title: Neoadjuvant short-term Intensive Chemoresection versus Standard Adjuvant intravesical instillations in NMIBC - A study on effect and tolerability of neoadjuvant short-term intensive chemoresection...
    Medical condition: Patients with recurrent non-muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000017467 10005004 Bladder cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003125-24 Sponsor Protocol Number: Clopidogrel_NSTEACS Start Date*: 2012-09-24
    Sponsor Name:A.O. UNIVERSITARIA INTEGRATA DI VERONA
    Full Title: Evaluation of platelet functional response in relation to the bioavailability of clopidogrel in patients with acute coronary syndromes without ST-segment elevation (NSTEACS).
    Medical condition: Patients with acute coronary syndromes without ST-segment elevation (NSTEACS).
    Disease: Version SOC Term Classification Code Term Level
    15.0 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022077-33 Sponsor Protocol Number: CaPaBe Start Date*: 2011-01-20
    Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA
    Full Title: Phase II, open label, study of primary chemotherapy with Bevacizumab in association with carboplatin, paclitaxel in early and locally advanced triple negative (ER, PgR and HER2 negative) breast ca...
    Medical condition: Patient with early and locally advanced triple negative (ER, PgR and HER2 negative) breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 17:36:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA